Share on StockTwits

Investment analysts at FBR Capital Markets decreased their price objective on shares of Novavax (NASDAQ:NVAX) from $11.00 to $10.00 in a note issued to investors on Thursday. The firm currently has an “outperform” rating on the stock. FBR Capital Markets’ price objective would suggest a potential upside of 118.34% from the company’s current price.

Novavax (NASDAQ:NVAX) traded down 7.53% during mid-day trading on Thursday, hitting $4.235. The stock had a trading volume of 1,913,694 shares. Novavax has a 52-week low of $2.24 and a 52-week high of $6.95. The stock has a 50-day moving average of $4.54 and a 200-day moving average of $4.83. The company’s market cap is $886.1 million.

Novavax (NASDAQ:NVAX) last posted its quarterly earnings results on Wednesday, August 6th. The company reported ($0.08) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.07) by $0.01. The company had revenue of $8.26 million for the quarter, compared to the consensus estimate of $8.74 million. During the same quarter last year, the company posted ($0.08) earnings per share. Novavax’s revenue was up 134.0% compared to the same quarter last year. Analysts expect that Novavax will post $-0.27 EPS for the current fiscal year.

Novavax, Inc (NASDAQ:NVAX), is a clinical stage biopharmaceutical company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.